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Benzothiazole is a heteroaromatic compound known for its wide range of
bioactivities including anti-cancer, anti-viral, anti-microbial, anti-inflammatory, anticonvulsant, anti-diabetic, anti-helminthic, and anti-tubercular activities. Research has
shown that derivatives of benzothiazole exhibit inhibition of proliferation via apoptosis in
various human cancer cell lines, such as liver cancer (Wang, et. al., 2011). In this study, a
series of novel hybrid benzothiazole α-cyanostilbene derivatives and styrylbenzothiazole
derivatives containing boronic acid and non-boronic acid pharmacophores were
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synthesized. The anti-cancer and anti-invasive properties of selected benzothiazole αcyanostilbene derivatives on U-87MG glioblastoma cells were investigated in vitro.
U-87MG cells were incubated with synthesized novel hybrid compounds at
varying concentration to determine the lethal concentration 50 (LC50) of the compounds.
All hybrid compounds displayed inhibitory effects on cell growth and the LC50 of the
compounds varied depending on the nature of the pharmacophores. Moreover,
compounds containing both boronic acid substituent and fluoro substituent exhibit lower
LC50 than those that contain only one of the substituents. Cell motility has been
investigated and we have found that was were no difference in motility between the
treated and untreated cells. Results indicate anti-invasive properties in boronic acid and
fluoro substituents at ortho position and boronic acid substituent at para position.
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CHAPTER 1

INTRODUCTION

Overview of Research Project
Cancer is one of the leading causes of death in the United States. Although
glioblastoma multiforme (GBM) is not common in the overall cancer population it is one
of the most lethal cancers, with a median survival of 12-15 months (Wen and Kesari,
2008). GBM is a malignant brain tumor that arises from astrocytes characterized by
invasive growth and proliferation. Unfortunately, it is also one of the most common type
of brain tumors in adults.
Glioblastoma is incurable due to its aggressive, rapid, invasive growth, and
proliferation. At present, surgical removal of the malignant tumor, followed by systemic
temozolomide chemotherapy and radiation therapy are used to treat GBM (Verhoeff et
al., 2009). Despite the aggressive therapies, less than 5% of treated GBM patients survive
5 years after treatment due to recurrence of GBM after surgical removal of the tumor; the
recurrence of GBM is often within the marginal tissues of the surgical removal site
(Gaspar et al., 1992). Furthermore, maximizing the treatment effects of chemotherapy,
surgery, and radiation therapy on a widely dispersed disease such as GBM could lead to
neurological impairment as well as a reduced quality of the patient’s life (Giese et al.,
2003).
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However, with the increase in understanding of GBM on a molecular level, new
therapeutic approaches have emerged. One possible novel therapeutic agent is
benzothiazole, a heterocyclic compound known for its wide range of biological properties
including anti-cancer activities, specifically anti-invasive properties (Ali and Siddiqui,
2013; Hiyoshi et al., 2014). In this project, I have synthesized and determined whether
novel hybrid benzothiazole derivatives can be used as anti-cancer and anti-invasion drugs
for glioblastoma cells.

Cancer
Cancer is among the leading causes of death worldwide and it has a major impact
on society. Humanity has been fighting cancer for centuries and while advancements are
made, there is still no cure for most cancers. The American Cancer Society (2019)
predicts that there will be 1,762,450 new cancer cases and about 606,880 Americans are
expected to die of cancer in 2019.
Cancer is a collection of
diseases characterized by uncontrolled
growth and the spread of abnormal cells
which results from atypical gene
expression and/or regulation, favoring
cell proliferation. Hanahan and

Figure 1 Hallmarks of Cancer. Six traits shared by
all forms of cancers as established by Hanahan
and Weinberg

Weinberg (2000) established six traits,
known as the hallmarks of cancer, shared by all forms of cancers. These include the
stimulation of self-growth, resistance to anti-growth signals, the ability to multiply
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indefinitely, resistance to apoptosis, the ability to sustain angiogenesis and the ability to
invade and metastasize (Fig 1).
While all of these traits play a role in cancer progression, invasion and metastasis
constitute a vital role in the progression of cancer. Invasion occurs when the malignant
cells migrate from the primary tumor mass to the local surrounding cells. The process of
invasion begins with the detachment of the cancer cells from the original tumor mass.
Subsequently, the tumor then secretes proteases which degrade the extracellular matrix.
The cancer cells go through morphological changes where protrusions such as
pseudopodia, lamellipodia, invadopodia and filopodia began to extend from the leading
edge of the cell. These protrusions begin forming membrane anchors, contracting the
cytoskeleton and allowing the cells to move forward (Nakada et al., 2007) (Fig. 2).

Figure 2 Invasion Cascade. Invasion occurs when the cancer cells moves from the
initial tumor mass and spread to local normal cells. The process of invasion
involves four main steps: detachment from the original, degradation of
extracellular matrix, formation of membrane protrusions, and migration.
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Metastasis is the dissemination of tumor cells from the primary site to a distant
secondary site (Fig 3). In metastasis, after penetrating through the extracellular matrix,
the migrating cell must arrive at the lymphatic or vascular system. Subsequently, the
migrating cell travels through the vascular/lymphatic system while evading the immune
system. The migrating cell then exits from the circulation, colonizes and proliferates at a
secondary site (Chan & Giaccia, 2007) (Fig. 3).

Figure 3 Metastatic Cascade. Metastasis occurs when the tumor cells
from the primary site spread to a secondary site.
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Brain Cancer
Brain cancer refers to the abnormal growth of cells in the brain. Although brain cancer is
relatively rare, it is among the leading causes of cancer death. Common primary brain
tumors include: glioma (tumor of the
glial cells), meningiomas (tumor of the
meninges), medulloblastoma (tumor of
the neuroectodermal cells in the
cerebellum), gangliogliomas (tumors of
neurons and glial cells), and
schwannomas (tumor of the Schwann

Figure 4 Classification of gliomas. Gliomas
are classified by their structural appearances.

cells).
Gliomas refers to all tumors that begin in the glial cells and are classified by their
structural appearances into three main groups: astrocytomas, oligodendrogliomas, and
ependymomas (Fig. 4). While relatively rare, constituting only about 5% of all cancers,
gliomas are the most proliferative. (American Cancer Society, 2016).
Astrocytomas are tumors that begin in the astrocytes. Astrocytes are star-shaped
glial cells that play a vital role in a variety of tasks, such as synaptic support, axon
guidance, maintenance of blood-brain barrier (Blackburn et al., 2009), maintenance of
ionic homeostasis in glia (Simard & Nedergaard, 2004), and maintenance of synaptic
homeostasis (Barbour et al., 1988). The interaction of astrocytes with neurons is essential
for the growth of the dendritic cells, effective synapse formation, and the removal of
unwanted synapses (Garwood et al., 2001). Astrocytomas make up about 80% of all
malignant brain tumors (American Cancer Society, 2016). The World Health
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Organization has classified astrocytomas into four grades based on their malignancy and
proliferation (Fig. 5).

Figure 5 Classification of Astrocytoma: Astrocytomas are classified into four grades
based on their proliferation and malignancy.

Glioblastoma Multiforme (GBM)
Glioblastoma multiforme (GBM) is the most common type of glioma. It is
extremely lethal due to its invasive growth and proliferative nature. The median survival
period for GBM is 12-15 months (Wen and Kesari, 2008).
Glioblastoma is incurable due to its aggressive and invasive growth, proliferative
nature, and destructive malignancy. Currently, GBM is treated through surgical removal,
followed by systemic temozolomide chemotherapy, and radiation therapy (Verhoeff et
al., 2009). However, fewer than 5% of the patients survive GBM after the treatment due
to recurrence of the tumor within the removal site. GBM also has poor prognosis as a
result of its aggressive nature. Although GBM does not metastasize outside the brain, it is
6

extremely successful in the invasion of surrounding normal brain cells. Understanding the
mechanism of invasion and key players involved in invasion can lead to development of
novel therapies for glioblastoma.
One of the key players of glioblastoma invasion is the gene family of matrixmetalloproteinases (MMPs) which degrade the extracellular matrix proteins, creating a
path for glioblastoma cells to invade surrounding normal brain tissues (Nakada et al.,
2003). Several MMPs have been shown to play in important role in cell migration not
only in central nervous system (CNS) but also in cell types outside the CNS. Ogier et al.
(2006) have shown that the constitutive expression of MMP-2 was observed in astrocyte
migration while MMP-9 expression was nearly undetectable. However, these two MMPs
(MMP-2 and MMP-9) have been shown to be highly upregulated in glioblastoma cells
and were correlated with increased invasion (Sawaya et al., 1996; Rao et al., 1996).
Another key player is the ADAM (a disintegrin and metalloproteinases) gene
family, a family of multidomain membrane-anchored proteins that also play an important
role in the invasion of glioblastoma cells. In normal cells, the members of the ADAM
family play an important role in cell adhesion and cell fusion events and are often highly
expressed in the brain, sperm and testis (Novak, 2004). Two ADAM members (ADAM12 and ADAM-17) aid glioblastoma cells to invade neighboring tissues. ADAM-17
cleaves CD44, an adhesion molecule which binds to an extracellular matrix component
(hyaluronic acid) and maintains cellular functions such as apoptosis, cell migration and
proliferation (Takamune et al., 2007; Ponta et al., 2003). ADAM 12 has been directly
correlated with proliferative activity and have been shown to be selectively expressed in
glioblastoma cells (Kodama et al., 2004). At present, there is no cure for glioblastoma.
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However, a better understanding of molecular mechanisms underlying the invasion of
glioblastoma offers the hope of developing novel therapies.

History of Drug Discovery
In the past, drug discovery has depended heavily on random screening. In
addition, the designing of novel drugs was based on the notion of a disease involving one
target (Gediya and Njar, 2009). While this has led to the discovery of numerous novel
drugs, the rate of drug discovery has decreased in recent years because new treatment
regimens are increasingly difficult to identify (Bolognesi and Cavalli, 2016). In recent
years, however, there is a growing interest in drugs that could impact multiple targets
simultaneously. Multi-targeted drugs can be more effective and less vulnerable to
resistance by the diseased cells through attack on multiple fronts (Zimmerman et al.,
2007).
One common multi-target drug therapy currently used in designing novel drugs is
the combination drug approach. Combination drugs, also known as drug cocktails, are
when two or more active pharmaceutical drugs are combined physically into a single
dosage form (Gautam and Saha, 2008). Compared to the single-target drugs, combination
drugs are less prone to drug resistance and have been used to control numerous complex
disease systems such as cancer. In combination chemotherapy, drugs that work through
different mechanisms of actions are used to decrease the possibility of resistance by
cancer cells to the treatment.
However, while combination drug therapy is highly effective, it also has multiple
limitations. For example, in combination chemotherapy there is an increased likelihood
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of side effects due to the increased number of drugs in the combination therapy. In
addition, due to the number of drugs involved, it is often difficult to know which drug
caused a specific side effect. Moreover, some side effects result not from a single drug,
but due to the drug interactions between the drugs involved in the therapy.
In recent years, there is an increasing interest in the development of multicomponent drugs where two or more pharmacophores are covalently linked into one
single drug. The notion of pharmacophore was first introduced by Ehrlich in 1909 as a
“molecular framework that carries the essential features responsible for a drug’s
biological activity” (Ehrlich, 1909). However, in 1998, IUPAC further elaborated
pharmacophores as “the ensemble of steric and electronic features that is necessary to
ensure the optimal supramolecular interactions with a specific biological target structure
and to trigger its biological response” (Langer and Hoffmann, 2006).
The concept of hybrid molecules was initially developed for the treatment of
malaria. However, this strategy has been applied to the treatment of multiple complex
disease systems such as cancer. One of the first hybrid anti-malarial drugs was reported
by Dechy-Cabaret et al. (2000), where artemisinin and chloroquine moieties were
covalently linked into one single molecule, trioxaquine. Trioxaquine has the properties of
both artemisinin (alkylating heme) and of chloroquine (blocking polymerization). In
2009, Cavalli and Bolognesi designed a novel compound for combating Trypanosoma
and Leishmania (Cavalli and Bolognesi, 2009).
Perhaps, the first hybrid drug and the only anti-cancer hybrid drug that's been
used clinically is estramustine (Gediya and Njar, 2009). Estramustine was initially
developed for the treatment of advanced prostate carcinoma (Jonsson et al., 1977) in
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1977. However, over the years, it has been combined with other chemotherapeutic drugs
to treat other forms of cancer such as glioblastoma multiforme (Piepmeier et al., 1993).
Hybrid drugs can be classified according to the type of linkage between the
pharmacophores (Fig 6). Directly linked hybrid drugs are attached by the functional
group of each pharmacophore which often results in an ester, a carbamate or an amide
that can be hydrolyzed enzymatically (e.g. lactandrate).
Spacer linked hybrid drugs are classified as either cleavable or non-cleavable.
Cleavable spacer linked hybrid drugs often contain ester linkages that can be cleaved by
the plasma esterases (e.g. NO-aspirin). This releases the two pharmacophores which act
independently. Non-cleavable spacer linked hybrid drugs contain a stable (in terms of
chemical and enzymatic) linkage that cannot be hydrolyzed (e.g. estradiol-anilin
mustard).
Merged/overlapped hybrid drugs contain pharmacophores that are overlapped
structurally and may retain the functional properties of both or either of the overlapped
drugs (e.g azatoxin). Hybrid drugs are often synthesized from drugs that have already
been developed. This is known as a post hoc approach. Another design of hybrids is
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known as the ad hoc approach where scaffolds with liabilities such as instability in vivo
are used for the synthesis of the hybrid drugs (Gediya and Njar 2009).
A

B
Cl

Cl

D

C

Figure 6 Example of types of hybrid drugs. A) Azatoxin B) Estradiol-Aniline Mustard C) NOAspirin D) Lactandrate

The hybrid compounds synthesized in this project can be classified as the
merged/overlapped hybrids. This
classification was due to the fact that all
synthesized hybrid compounds contain
a stilbene pharmacophore upon which
other pharmacophores are directly

Figure 7 Example of synthesized compound. Blue:
stilbene component, Red: Benzothiazole
component, Yellow: cyano/nitrile component,
Green: Boronic acid component

attached, merged or embedded (Fig 7).
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Novel Hybrid Benzothiazoles
In recent years, heterocyclic compound analogs and derivatives have been studied
extensively due to their potential as new therapeutic agents against cancer. Heterocyclic
compounds are cyclic rings with one or more different elements and they contain either
nitrogen, oxygen, or sulfur within the ring. Heterocyclic compounds have been reported
to display biological activities such as anti-fungal, anti-inflammatory, anti-convulsant,
herbicidal and anti-cancer (Saini et al., 2013). Due to their wide range of biological
activities, heterocyclic compounds can be found in a majority of medical and
pharmaceutical drugs. An example of one heterocyclic compound that is currently used
as a treatment for glioblastoma is temozolomide, . Heterocyclic compounds exist in two
forms: aromatic and non-aromatic (Fig. 8). Heteroaromatic compounds are flat molecules
that contain alternating double and single bonds and obey Hückel's rule (4n + 2 π
electrons). Hetero non-aromatic compounds are those that do not contain double bonds.

Hetero non-aromatic

Figure 8 Example of heteroaromatic (left) compounds and hetero non-aromatic (right)
compounds. Heteroaromatic compounds contain double bounds while hetero non-aromatic
compounds do not contain any double bounds.

Benzothiazole is among these heterocyclic compounds, specifically
heteroaromatic compounds, and has a wide range of biological activities including anti12

tumor, anti-helmintic, analgesic, anti-diabetic, anti-malarial, anti-tubercular, antiinflammatory, anti-convulsant, and diuretic (Singh and Singh, 2014). Due to its
aromaticity which makes the compound extremely stable, benzothiazole has been used as
a scaffold to synthesize a large number of therapeutic agents (Ali and Siddiqui, 2013).
Studies have shown the ability of benzothiazole derivatives to inhibit proliferation and
invasiveness in breast cancer, colon cancer, and lung cancer (Hiyoshi et al., 2014;
Mortimer et al., 2005; Wang et al., 2011); but to my knowledge, no published studies
have investigated the therapeutic use of benzothiazole derivatives on glioblastoma.
One of the goals for this study is to synthesize novel hybrid benzothiazole
compounds. One specific functional group of interest to hybridize with the benzothiazole
is boronic acid. Boronic acids are compounds containing boron and two hydroxyl (-OH)
groups and they have been shown to display bioactivities such as anti-cancer, antimicrobial, and anti-viral (Trippier and McGuigan, 2010). Due to their unique structural
features, boronic acids have been used to develop potent enzyme inhibitors, as antibody
mimics that recognize biologically important saccharides, and boron neutron capture
agents for cancer therapy (Yang et al., 2003). Consequently, there is a growing interest in
boronic acid containing drugs. Currently, there are only two FDA approved boronic acid
containing drugs. Among them is bortezomib (Velcade®), used for the treatment of
relapsed multiple myeloma and mantle cell lymphoma (Trippier and McGuigen, 2010).
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Predicted Bioavailability and Blood-brain barrier Permeability of Novel Hybrid
Benzothiazoles
Lipophilicity
Lipophilicity plays an important role in the design and discovery of novel drugs.
Lipophilic properties of a compound can be described using the octanol-water partition
coefficient (LogP) which is the ratio of the concentration of the unionized molecule at
equilibrium between aqueous and organic phases. Lipophilic compounds have the ability
to dissolve in fats, oils, lipids and non-polar solvents. Lipophilicity is not synonymous
with hydrophobicity. While hydrophobic compounds describe the interaction between the
compound and water, lipophilic compounds interact with lipids. Lipophilicity of a
compound affects its solubility, permeability, potency, selectivity, absorption,
metabolism, and toxicity (Gao et al., 2017).

Oral Bioavailability
Oral bioavailability of novel hybrid benzothiazoles can be measured using
Lipinski’s rule of five. This method of measurement is commonly used when new drugs
are designed and developed, and the oral bioavailability of the potential drug molecule is
unknown. According to Lipinski’s rule, the molecules would be orally active if: 1) the
number of hydrogen-bond donors is less than five, 2) the molecular mass is less than 500,
3) calculated octanol-water partition coefficient (Log P) is less than five, and 4) the
number of hydrogen acceptors is less than ten. Drugs that are orally active generally do
not violate any of the above rules. In addition to Lipinski’s rule of five, Veber et al.
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(2002) added two more rules to improve the predictions of drug-likeness. They are as
follows: 1) 10 or fewer rotatable bonds and 2) polar surface no greater than 140 Å.

Blood-Brain Barrier Penetration
Because the human brain is a
highly sensitive and fragile neuronal
organ system that requires high
maintenance and regular supply of
nutrients, fuels, and gases, the bloodbrain barrier acts as a protective barrier
that imposes various obstacles for
foreign substances. The blood-brain
barrier inhibits delivery of various
therapeutic drugs and imposes an

Figure 9 Blood-brain barrier acts as a
protective barrier that prevents the entry of
various foreign substances.

obstruction for delivery of a large number of drugs (Updahyay, 2014). The endothelial
cells that make up the tight junction and their lack of fenestration preclude paracellular
diffusion (Fig. 9). Therefore, the majority of drug blood-brain barrier penetration occurs
through the passive diffusion through the cellular membrane (Pajouhesh and Lenz 2005).
Here, I have investigated the potential therapeutic role of novel benzothiazole
derivatives. In this study I have 1) predicted the bioavalability and the blood-brain barrier
permeability of designed novel hybrid benzothiazoles, 2) synthesized novel hybrid
benzothiazoles, and 3) determined the anti-cancer and/or anti-invasive properties of the
novel compounds by treating U-87MG glioblastoma cells with these compounds. I
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hypothesize that benzothiazole containing compounds will inhibit the growth of U-87MG
glioblastoma cells and exhibit anti-cancer/anti-invasive properties.
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CHAPTER 2

METHODOLOGY

Candidate Novel Hybrid Benzothiazole Structures and Calculation of their
Molecular Properties
The ChemSketch tool and Marvin JS by ChemAxon were used to draw all the
hybrid molecules. Online server such as Molinspiration was employed to predict the
biological properties of the tested hybrid molecules. . Percent of absorption was
calculated using the modified equation % absorption = 109 – 0.345 x TPSA from Zhao et
al. (2002). All figures were drawn using softwares such as ChemDoodle and BioRender.

Chemistry
Materials
The reagents and solvents used throughout the synthesis and analysis were
commercially purchased from Sigma-Aldrich. The experiments were conducted under a
conventional fume hood using a magnetic stirrer. IR spectra was obtained using Thermo
Scientific Nicolet iS50 ATR Infrared Spectroscopy. NMR spectra was obtained using
JEOL JNM-ECP400 FT NMR system, Eclipse400 FT NMR spectrometer, and Delta
software.
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Experimental Procedures
Benzothiazole α-cyanostilbenes
32 ml of water and 8 ml of ethanol was added into a clean and oven dried 50 ml
round bottom flask containing a magnetic stir bar. After clamping the flask in place on a
magnetic hot plate stirrer, the reagents
were added in the following order: 1) 2.5
mmol aromatic aldehyde containing or not
containing boronic acid, 2) 2.5 mmol
benzothiazole-2-acetonitrile, 3) 10 mmol
of calcium oxide (CaO). This mixture was
refluxed for three hours in a conventional
fume hood (Fig 10). After the reflux
reaction was completed, the mixture was

Figure 10 Reflux setup
was used to synthesize
novel hybrid
benzothiazole α-

cyanostilbenes

Figure 11 Vacuum
filter setup was used
to separate the solid
product from the
mixture.

placed into a beaker containing ice and 30 ml of saturated ammonium chloride (NH4Cl)
and stirred on a magnetic stirrer until neutralization had taken place. Neutralization was
established by measuring pH using litmus pH test strips. The neutralized mixture was
vacuum-filtered and air-dried for up to 48 h (Fig 11). The
resulting products were weighted and characterized by
obtaining their IR and NMR spectra and comparing with
the IR and NMR spectra of the organic starting materials.
After analyzing the products, they were further
purified using extraction methods. The product was
extracted three times. The resulting product was further
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Figure 12 Extraction and
washing setup were used to
purify the products to prevent
the presence of CaO

purified by washing. Deionized water and saturated sodium
chloride were used as inorganic solvents and ethyl acetate
was used as the organic solvent (Fig 12). Ethyl acetate was
then evaporated using the rotary evaporator (Fig 13) and the
product was air dried overnight and analyzed using IR and
NMR spectroscopy.
Figure 13 Rotary evaporator
was used to remove the
organic solvent

Styrylbenzothiazole
Preliminary tests were conducted to optimize synthesis of styrylbenzothiazoles.
15 ml of fresh dry dimethylformamide (DMF) was syringed into an oven-dried 50 ml
round bottom flask containing a magnetic stir bar. A CaCl2 drying tube was attached to
the round bottom flask and the whole apparatus was clamped in place on a magnetic
stirrer (Fig 14). The reagents were measured out and added to the flask in the following
order: 1) 12.5 mmol lithium hydride, 2) 7.5 mmol potassium t-butoxide (KTB), 3) 2.5
mmol aromatic aldehyde with subunits containing/not
containing boronic acid. The mixture was stirred at
room temperature for four hours in a conventional
fume hood. At the completion of the reaction, the
mixture was poured into a beaker containing ice and
30 ml of saturated NH4Cl. The mixture was stirred for
10 mins on a magnetic stirrer until neutralization had
Figure 14 Synthesis of
styrylbenzothiazole was achieved
by stirring the starting materials at
room temperature

taken place. Neutralization was established by
measuring pH using litmus pH test strips. After
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neutralization, the mixture was vacuum filtered and air dried overnight. The resulting
products were weighted and characterized by obtaining their IR and NMR spectra and
comparing with the IR and NMR spectra of the organic starting materials.

Diagnostic IR and NMR Peaks
IR spectroscopy was used to identify the novel hybrid compound and determined
the presence and absence of the functional group in the mixture. NMR was used to
further determine the molecular structure and the purity of the synthesized compounds.
The following are the diagnostic IR and 1H NMR peaks expected to be observed in the
synthesized compounds.

Styrylbenzothiazole:
Starting Materials: Methylbenzothiazole. The diagnostic IR peaks (cm-3) for
methylbenzothiazole include: 1250-1020 (C-N), 1500-1400 (C-C aromatic), 3000-3100
(C-H aromatic), 2850-3000 (C-H alkane). Diagnostic 1H NMR peaks for (δ) for
methylbenzothiazole include: 3.0 (CH3), 7.5-8 (aromatic H), ~2.5 (H-C-N).
Formylphenylboronic acid: The diagnostic IR peaks for formylphenylboronic acid
include: 1710 (C=O aldehyde), 1300-1400 (B-O), 3200-3500 (O-H). For the 1H NMR
spectrum, we should see peaks at 9.7-10 (C=O aldehyde), 7-8 (aromatic H), 2-5 (O-H).
The disappearance of the methyl peak at 2850-3000 (C-H alkane) and of the
aldehyde peak at 1710 (C=O aldehyde) from the IR spectrum and methyl peak at 3.0
(CH3) and aldehyde peak at 9.7-10 (C=O aldehyde) from 1H NMR spectrum would
indicate the formation of the desired product. In addition, we should see the formation of
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C=C in the product which would be indicated by the peak at 1680-1640 from IR
spectrum and ~7.0 from 1H NMR spectrum.

Benzothiazole α-cyanostilbenes
Starting Materials: Benzothiazoleacteonitrile. The diagnostic IR peaks of (cm-3)
for benzothiazoleacetonitrile include: 2210-2260 (CN stretch), 1500-1400 (C-C
aromatic), 3000-3100 (C-H aromatic), 2300-2000 (nitrile). Diagnostic 1H NMR (δ) peaks
include: 2.0-3.0 (nitrile),7.5-8.0 (aromatic H). Formylphenylboronic acid: The diagnostic
IR peaks for formylphenylboronic acid include: 1710 (C=O aldehyde), 1300-1400 (B-O),
3200-3500 (O-H). For the 1H NMR spectrum, we should see peaks at 9.7-10 (C=O
aldehyde), 7-8 (aromatic H), 2-5 (O-H).
The aldehyde peak should disappear from both IR and 1H NMR if the desired
product is formed. We should still see the nitrile peak at 2300-2000 for IR spectrum and
at 2.0-3.0 for 1H NMR spectrum. In addition, the formation of C=C bond should be seen
on both 1H NMR (~7.0) and IR (1680-160) spectrum if the product is present.

Biology
Maintaining U-87MG Glioblastoma Cell Line
U-87MG glioblastomaa cells (ATCC) were grown and maintained in MEM
(Minimum Essential Medium) supplemented with 10% fetal bovine serum (Gibco), and
100U/ml penicillin/streptomycin solution (Gibco). The cells were kept in a humidified
37˚C, 5% CO2 incubator. Every 48 h I observed the density of the cells in the plate, using
a light microscope. When the density was low, the media was removed and replaced with
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new media. However, when the density reached approximately 80%, the cell density was
reduced by removing the old media and placing 2 ml of trypsin/EDTA (Gibco) on the
cells for detachment, then removing half of the cells in the trypsin/EDTA solution, and
lastly, adding 8 ml of new media to the plate.
Compound Preparation
Stock samples were prepared to evaluate the cell viability after they were treated
with novel hybrid benzothiazoles. This preparation was completed at least 24 h prior to
the experiment. To prepare the samples, 0.02 g of novel compounds were dissolved in 1
ml of dimethyl sulfoxide (DMSO). Previous studies in our lab have shown that 1%
DMSO or less had no effect on cell viability.
Eight of the synthesized novel hybrid benzothiazole α-cyanostilbenes were
selected for screening for their anti-cancer properties. These compounds were selected
based on the heterocyclic subunit in the hybrid molecule containing boronic acid, nonboronic acid (fluoro), or both (fluoro and boronic acid) at ortho, meta, and para positions.
Focusing on these compounds will allow us to compare the effects of position on the
aromatic ring, as well as the effects of boronic versus nonboronic acid compounds. These
compounds were also compared to selected starting materials.
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Treatment of U-87MG Glioblastoma Cells
Novel hybrid compounds at varying concentration diluted in media (2.0 mg/ml,
1.0 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125
mg/ml, 0.0625 mg/ml, 0.03125 mg/ml,
0.015625 mg/ml, 0.0078125 mg/ml,
0.003906 mg/ml, 0.001953 mg/ml) were
placed in eleven wells of a CorningTM
CostarTM flat bottom 12-well cell culture
Figure 15 12-Well Plate Setup

plate. The control well contained untreated
cells that were only exposed to the cell culture media (Fig 15).

Cell Viability Assay
Preliminary tests were conducted to determine a suitable cell viability assay
which accurately reflected the lethal concentration (LC50) of the novel hybrid
compounds. A modified NIH cell viability assay was used to determine the effect of the
novel hybrid compounds on U-87MG glioblastoma cell viability. The viability of U87MG cells was determined after the cells were treated with varying concentrations of
novel hybrid compounds. U-87MG cells were introduced into a CorningTM CostarTM flat
bottom 12-well cell culture plate at the concentration of 10,000 cells/well. The cell count
was estimated using the trypan blue exclusion method (Gibco) and a hemocytometer.
After the cells were introduced, they were placed into a humidified, 37˚C and 5%
CO2 incubator for 24 h. Once the incubation period had elapsed, the cells were treated at
varying concentration (2.0 mg/ml, 1.0 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml,
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0.0625 mg/ml, 0.03125 mg/ml, 0.015625 mg/ml, 0.0078125 mg/ml, 0.003906 mg/ml,
0.001953 mg/ml) of novel hybrid benzothiazoles and incubated for 24 h under the
conditions mentioned above.
At the end of the treatment period, the drug was removed, 1 ml of methanol was
added to each of the wells and the cells were fixed for 5 mins. Methanol was removed at
the end of the fixation, and crystal violet was added to the wells to stain the cells. The
cells were then stained for 5 mins, washed and air-dried overnight. The stained cells were
quantified using an inverted light microscope at 400x, with three individual fields per
well counted and averaged (Fig 16). Each compound cell viability assay was repeated
three times. The LC50 for each compound was determined using linear regression.

Figure 16 Cell Viability Assay Setup. Cells from the stock plate were introduced to the plate and
was incubated. Cells were treated with compounds for 24hrs and were stained and counted.

Confirmation of Lethal Concentration (LC50)
To confirm that the LC50 values obtained from the cell viability assay were
accurate, each calculated compound LC50 concentration was tested an additional nine
times. The cells for each trial were obtained from new stock cultures. 50,000 cells were
introduced in each of the 24 wells of a CorningTM CostarTM flat bottom culture plates and
incubated for 24 h in a humidified, 37˚C, and 5% CO2 incubator. The cells were then
treated with the LC50 of the novel hybrid benzothiazoles and incubated as above for 24 h.
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At the end of the treatment, the cells were fixed and stained under the conditions
mentioned above.

Wound Healing Scratch Assay
A modified wound healing scratch assay was performed to determine the effect of
the novel hybrid benzothiazoles on motility of the U-87MG glioblastoma cells. 200,000
cells were introduced into 60 mm Thermo ScientificTM NuncTM Cell Culture dishes and
grown in MEM supplemented with 10% FBS and 100U/ml penicillin/streptomycin. The
cells were allowed to grow in a 5% CO2 humidified environment at 37°C until they
reached 100% confluency as a monolayer (approximately 3 days). When the cells
reached 100% confluency, a sterile 200 µl pipette tip was used to scratch the monolayer
across the center of the dish (Fig 17). After creating the scratch, the media was gently
Scratch
across the
plate

removed via vacuum suction to remove the
detached cells. The dish was then
replenished with fresh medium in the
control plate and test compounds at the
lowest tested concentration (LTC) and the
highest concentration that resembles the
control (HCRC) plate (Table 1). Migration

Figure 17 Scratch assay on 60mm dish. A
scratch was made across the 100% confluent
cell layer and were treated up to 24hrs.

process was documented by taking sequential digital photographs of the ‘wound’ using
the inverted light microscope. Digital photographs were taken every 24 h for two days.
Each concentration was evaluated in triplicate.
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Table 1 Concentrations Used for Wound Healing Scratch Assay
Novel Hybrid Benzothiazole (mg/ml)
PKP2

LTC

PKP3

PKP4

PKP5

PKP6

PKP7

3F-

4F-

2BA

3BA

0.00195 0.00195 0.00195 0.00195 0.00195 0.00195 0.00195 0.00195

HCRC 0.00195 0.00195 0.00195 0.00781 0.00781 0.00781 0.00195 0.00195

*LTC = Lowest tested concentration; HCRC = Highest concentration that resembles the
control
Neurosphere Assay
The effect of the novel hybrid benzothiazoles on the site of tumor initiation
(neurospheres) was determined by performing the neurosphere assay. In this assay, the
cells were seeded in 24 wells CorningTM CostarTM flat bottom culture plates at a
concentration of 50,000 cells per 500 µl, estimated by the trypan blue exclusion method.
After introduction of the cells, the plates were incubated for 24 h in a 5% CO2
humidified incubator at 37°C to allow for cell attachment. Once the 24 h had passed, the
media was removed and replaced with the LC50 and the LTC of the tested compounds.
The cells were treated with novel hybrid compounds for a total of six days at the
conditions mentioned above (Fig 18). After 24 h of treatment, the media from day one
cells of both treated and untreated wells were removed and the cells were fixed and
stained under the aforementioned conditions. The plates were returned to the incubator
until the next assay day. Fixing and staining methods were repeated at day 3 and day 6 of
the treatment. Neurospheres were assessed by determining their number and size.
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Figure 18 Neurosphere Assay Setup. Cells were introduced and were treated at
LC50 and HCRC of the tested compounds. Neurosphere formation was observed
at the indicated time points.

Invasion Assay
Following the instructions from the CytoSelectTM Cell Ianvasion Assay Kit, U87MG cells were suspended in serum free media. Novel hybrid benzothiazoles at HCRC
were added directly to the cell suspension. The cell suspension with the novel compounds
were kept for 24 hours at 37˚C 5% CO2 in a humidified incubator to allow the invasive
cells to pass through the basement membrane and cling to the bottom of the insert while
the non-invasive cells stay in the upper chamber. After the incubation period, the noninvasive cells were removed, and the invasive cells were stained. Stained invasive cells
were quantified using the light microscope. The effect of the novel hybrid benzothiazoles
on the invasiveness of GBM cells was analyzed by comparing the results of treated and
untreated cells (Fig 19).
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Figure 19 Invasion assay principle based on CytoSelectTM Cell Invasion Assay Kit.
Cells were suspended in the serum free media containing/lacking test compounds.
The cells were incubated for 24hrs and invasive cells were quantified.

Statistical Analysis
The significant difference between the concentrations and the control of each test
compounds were calculated via one-way ANOVA with Dunette-adjusted post hoc test on
IBM SPSS software. The significant difference of the invasion assay was determined via
one-way ANOVA with Bonferroni-adjusted post hoc test on IBM SPSS software.
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CHAPTER 3

RESULTS

Predicted Bioavailability and Blood-brain barrier Permeability of Novel Hybrid
Compounds
Molecular properties for novel hybrid benzothiazoles were calculated using an
online software, Molinspiration (http://www.molinspiration.com// cgi-bin/properties) and
the values are given in Table 2.

Table 2 Predicted Molecular Properties of Novel Hybrid Benzothiazole Derivatives

1.
2.
3.
4.
5.

Compound

LogP1

TPSA2

nAtoms3

nON4

nOHNH5

MW6

nRotB7

% ABS8

R59

PKP2

3.00

77.14

22

4

2

306.15

3

82.38

Pass

PKP3

2.77

77.14

22

4

2

306.15

3

82.38

Pass

PKP4

2.97

77.14

22

4

2

306.15

3

82.38

Pass

PKP5

3.89

36.68

20

2

0

280.33

2

96.34

Pass

PKP6

4.11

36.68

20

2

0

280.33

2

96.34

Pass

PKP7

4.09

36.68

20

2

0

280.33

2

96.34

Pass

4F-3BA

2.91

77.14

23

4

2

324.14

3

82.38

Pass

3F-4BA

2.88

77.14

23

4

2

324.14

3

82.38

Pass

Octanol-water partition coefficient
Topological polar surface area
Number of atoms
Number of hydrogen-bond acceptor
Number of hydrogen-bond donor

6. Molecular weight
7. Number of rotatable bonds
8. Percent absorption
9. Lipinski’s rule of five violation
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Chemistry
All benzothiazole α-cyanostilbenes products and styrylbenzothiazoles products
were weighed and characterized by 1H NMR and IR spectroscopy. Data for the novel
hybrid compounds are shown below.

4-boronic acid-α-cyanobenzothiazolestilbene (PKP2)
Yield: 115.6%; IR (ATR, cm-1): 2227 (C≡N stretch), 3364 (O-H), 1429 (B-O); 1H NMR
(400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.8 (2H, d, Ar-H),
8.2 (1H, s, CH)

3-boronic acid-α-cyanobenzothiazolestilbene (PKP4)
Yield: 108.8%; IR (ATR, cm-1): 2223 (C≡N stretch), 3120 (O-H), 1397 (B-O); 1H NMR
(400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.5-8.0 (1H, m, ArH), 8.2 (1H, s, CH)

2-boronic acid-α-cyanobenzothiazolestilbene (PKP3)
Yield: 73.03%; IR (ATR, cm-1): 2215 (C≡N stretch), 3134 (O-H), 1404 (B-O); 1H NMR
(400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.5-8.0 (4H, m, Ar-H), 7.2-7.8 (1H, m, ArH), 8.2 (1H, s, CH)

2-fluoro-α-cyanobenzothiazolestilbene (PKP5)
Yield: 87.9%; IR (ATR, cm-1): 3054 (=C-H), 2227 (C≡N stretch), 1241 (C-F); 1H NMR
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.3-7.8 (1H, m, Ar-H), 8.0 (1H, s,
CH)

3-fluoro-α-cyanobenzothiazolestilbene (PKP7)
Yield: 101.6%; IR (ATR, cm-1): 3057 (=C-H), 2218 (C≡N stretch), 1193 (C-F); 1H NMR
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.1-7.3 (1H, m, Ar-H), 8.2 (1H, s,
CH)
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4-fluoro-α-cyanobenzothiazolestilbene (PKP6)
Yield: 98.28%; IR (ATR, cm-1): 3054 (=C-H), 2227 (C≡N stretch), 1241 (C-F); 1H NMR
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.4-7.5 (2H, d, Ar-H), 8.1 (1H, s, CH)
3-(trifluoromethyl)- α-cyanobenzothiazolestilbene (PKP8)
Yield: 98.20%; IR (ATR, cm-1): (=C-H), 2234 (C≡N stretch), 1203 (C-F); 1H NMR (400
MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.5-7.8 (2H, d, Ar-H), 8.2 (1H, s, CH)
4-(trifluoromethyl)- α-cyanobenzothiazolestilbene (PKP9)
Yield: 98.40%; IR (ATR, cm-1): 3061 (=C-H), 2234 (C≡N stretch), 1322 (C-F); 1H NMR
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.7-7.8 (2H, d, Ar-H), 8.1 (1H, s, CH)

2-chloro-α-cyanobenzothiazolestilbene (PKP10)
Yield: 114.80%; IR (ATR, cm-1): 3042 (=C-H), 2226 (C≡N stretch), 751 (C-Cl); 1H
NMR (400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.3-7.8 (1H, d, Ar-H), 8.0 (1H,
s, CH)

3-chloro-α-cyanobenzothiazolestilbene (PKP11)
Yield: 89.90%; IR (ATR, cm-1): 3032 (=C-H), 2236 (C≡N stretch), 724 (C-Cl); 1H NMR
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.5-8.1 (1H, d, Ar-H), 8.2 (1H, s, CH)

4-chloro-α-cyanobenzothiazolestilbene (PKP12)
Yield: 108.6%; IR (ATR, cm-1): 3032 (=C-H), 2221 (C≡N stretch), 758 (C-Cl); 1H NMR
(400 MHz, Methanol-d3) δ: 7.4-7.8 (4H, m, Ar-H), 7.5-7.6 (2H, d, Ar-H), 8.1 (1H, s, CH)
α-cyanobenzothiazole-2-thiophene-stilbene (PKP13)
Yield: 108.60%; IR (ATR, cm-1): 3057 (=C-H), 2212 (C-S); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.3 (1H, d, Ar-H), 7.4 (1H, d, CH)

31

5-methyl-α-cyanobenzothiazole-2-thiophenestilbene (PKP14)
Yield: 92.45%; IR (ATR, cm-1): 3059 (=C-H), 2225 (C-S); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.0-7.1 (1H, d, Ar-H), 7.4 (1H, d, CH), 2.3 (3H,
s, CH)

2-fluoro-5-boronic acid-α-cyanobenzothiazolestilbene (PKP15)
Yield: 108.58%; IR (ATR, cm-1): 3032 (=C-H), 2221 (C≡N stretch), 1404 (B-O); 1H
NMR (400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.5-7.6 (1H, d,
Ar-H), 8.2 (1H, s, CH)

2-fluoro-4-boronic acid-α-cyanobenzothiazolestilbene (PKP16)
Yield: 101.58%; IR (ATR, cm-1): 3058 (O-H), 2218 (C≡N stretch), 1422 (B-O); 1H
NMR (400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-7.9 (4H, m, Ar-H), 7.4-7.7 (1H, d,
Ar-H), 8.3 (1H, s, CH)

4-fluoro-3-boronic acid-α-cyanobenzothiazolestilbene (4F-3BA)
Yield: 116.60%; IR (ATR, cm-1): 3350 (O-H), 3058 (=C-H), 2218 (C≡N stretch), 1422
(B-O); 1H NMR (400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.67.7 (1H, d, Ar-H), 8.1 (1H, s, CH)

3-fluoro-2-boronic acid-α-cyanobenzothiazolestilbene (3F-2BA)
Yield: 49.78%; IR (ATR, cm-1): 3350 (O-H), 1411 (B-O), 1234 (C-F); 1H NMR (400
MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.2-7.5 (1H, d, Ar-H), 8.2
(1H, s, CH)

4-chloro-styrylbenzothiazole (PKP17)
Yield: 94.45%; IR (ATR, cm-1): 3054 (=C-H), 752 (C-Cl); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.7 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH)
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3-chloro-styrylbenzothiazole (PKP18)
Yield: 97.80%; IR (ATR, cm-1): 3052 (=C-H), 755 (C-Cl); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.3-7.5 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH)

2-chloro-styrylbenzothiazole (PKP19)
Yield: 89.90%; IR (ATR, cm-1): 3054 (=C-H), 752 (C-Cl); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.7 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH)

2-fluoro-styrylbenzothiazole (PKP20)
Yield: 72.90%; IR (ATR, cm-1): 3057 (=C-H), 1234 (C-F); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.7 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH)

3-fluoro-styrylbenzothiazole (PKP21)
Yield: 97.60%; IR (ATR, cm-1): 3052 (=C-H), 1246 (C-F); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.0-7.4 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH)

4-fluoro-styrylbenzothiazole (PKP22)
Yield: 97.80%; IR (ATR, cm-1): 3039 (=C-H), 1223 (C-F); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.6 (2H, d, Ar-H), 7.3-7.4 (1H, d, CH)

2-(trifluoromethyl)-styrylbenzothiazole (PKP23)
Yield: 82.77%; IR (ATR, cm-1): 3053 (=C-H), 1102 (C-F); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.7 (1H, d, Ar-H), 7.3-7.6 (1H, d, CH)

3-(trifluoromethyl)-styrylbenzothiazole (PKP23
Yield: 91.1%; IR (ATR, cm-1): 3059 (=C-H), 1117 (C-F); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.7 (2H, d, Ar-H), 7.3-7.5 (1H, d, CH)

4-(trifluoromethyl)-styrylbenzothiazole (PKP24)
Yield: 81.00%; IR (ATR, cm-1): 3060 (=C-H), 1322 (C-F); 1H NMR (400 MHz,
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.4-8.0 (1H, d, Ar-H), 7.3-7.4 (1H, d, CH)
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Table 3 shows the structures of the reactants and the products in details.
Benzothiazole α-cyanostilbenes were obtained in yields ranging from 49.78% to
116.60%, with the substituent 3-fluoro-2-formylphenylboronic acid having the lowest
yield and the substituent 4-fluoro-3-formylphenylboronic acid having the highest yield.
Overall, functional groups that are ortho-substituted have lower percent yield compared
to those that are meta- and para-substituted, with the exception of the
chlorobenzaldehyde substituents.
Styrylbenzothiazoles were obtained in yields ranging from 72.90% to 97.80%,
with the substituent 2-fluorobenzaldehyde having the lowest yield and substituents 2chlorobenzaldehyde and 4-fluorobenzaldehyde having the highest yield. In this family,
there seems to be no relationship between the substituents’ positions and the products’
yield.

Table 3 Reactants and product structures
2-Benzothiazole
Reactant

Aldehyde Reactant

2-Benzothiazole Product

Percent
Yield
(%)

ɑ-Cyanostilbenes

-Acetonitrile
4-formylphenolboronic
acid

PKP2
115.6

3-formylphenolboronic
acid

PKP4
108.8
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2-formylphenolboronic
acid

PKP3
73.03

2-fluorobenzaldehyde

PKP5
87.9

3-fluorobenaldehyde

PKP7
101.6

4-fluorobenzaldehyde

PKP6
98.28

3-(trifluoromethyl)
benzaldehyde

PKP8
98.2

4-(trifluoromethyl)
benzaldehyde

PKP9
98.40

2-chlorobenzadehyde

PKP10
114.80
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3-chlorobenzaldehyde

PKP11
102.80

4-chlorobenzaldehyde

PKP12
108.60

2-thiophenecarboxaldehyde

PKP13
108.60

5-methyl-2-thiophenecarboxaldehyde

PKP14
92.45

2-fluoro-5formylphenylboronic
acid

PKP15

2-fluoro-4formylphenylboronic
acid

PKP16

108.58

101.94

4-fluoro-3formylphenylboronic
acid

4F-3BA
116.60
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3-fluoro-2formylphenylboronic
acid

3F-2BA
49.78

-Methyl

Styryl
4-chlorobenzaldehyde

PKP17
94.45

2-chlorobenzaldehyde
97.80

3-chlorobenzaldehyde

PKP18
89.90

2-fluorobenzaldehyde

PKP19
72.90

3-fluorobenzaldehyde

PKP20
97.60

4-fluorobenzaldehyde

PKP21
97.80
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2-(trifluoromethyl)benzaldehyde

PKP22
82.77

3-(trifluoromethyl)benzaldehyde

PKP23
91.1

4-(trifluoromethyl)benzaldehyde

PKP24
81.00

Biology
Cell Viability Assay
The viability of U-87MG cells was determined after the cells were treated with
varying concentrations of the novel hybrid benzothiazoles to establish their LC50 values.
The LC50 values of the compounds were converted into µM from mg/ml (Table 4).
Table 4 Tested compounds represented in µM
TESTED COMPOUND

LC50 (MG/ML)

LC50 (µM)

PKP2

0.08125

265.392

PKP3

0.0625

204.14

PKP4

0.03125

102.07

PKP5

0.0625

280.33

PKP6

0.09375

334.42
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PKP7

0.0875

312.13

4F-3BA

0.01175

36.25

3F-2BA

0.05625

173.53

Figure 20 shows the cell viability at all eleven concentrations and the red arrow
indicates the LC50 of the compounds. Benzothiazoles containing boronic acid substituents
at para, meta, and ortho positions are shown in Figure 20, A to C (PKP2, PKP4, PKP3).
While all positions showed a reduction in cell viability, meta position had the lowest
LC50 value (0.03125 mg/ml) and ortho position had the highest LC50 value (0.08125
mg/ml).
Figure 20, D to F (PKP6, PKP7, PKP5) shows the effects of benzothiazoles with
fluoro substituents on U-87MG cell viability. All three positions showed a reduction in
cell viability, with ortho position having the lowest LC50 value (0.0625 mg/ml) and para
position having the highest LC50 value (0.09375 mg/ml). The results showed cell growth
at the higher concentration (2 mg/ml to 0.5 mg/ml) PKP4 and PKP3. However, the cells
did not look normal; they lacked the shape of glioblastoma cells and were round in shape.
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Figure 20 The effect of novel hybrid benzothiazoles on U-87MG glioblastoma cell viability compared
to untreated U-87MG cells. Red arrows indicate the LC50 values of each compound. A: PKP2Boronic acid substituent at para position; B: PKP4-Boronic acid substituent at met position; C:
PKP3-Boronic acid substituent at meta position. D: PKP6-Fluoro substituent at para position; E:
PKP7-Fluoro substituent at meta position; F: PKP5-Fluoro substituent at ortho position; G: 4F-2BABoronic acid substituent at meta position and fluoro substituent at para position to boronic acid
substituent; H: 3F-2BA-Boronic acid substituent at ortho position and fluoro substituent at meta
position to boronic acid substituent. Asterisks represent the lowest concentration with a statistically
significance difference from control p ≤ 0.05. Error bars indicate standard error, n = 3 independent
experiments in triplicate.

Treatment with benzothiazoles containing both fluoro and boronic acid
substituents are shown in Figure 18, G and H (4F-3BA, 3F-3BA). Both compounds
display decreases in cell viability. However, benzothiazole containing boronic acid at
meta position and fluoro at para position of the boronic acid substituent had the lowest
LC50 among all of the tested compounds.
The results of the novel hybrid compounds were compared with the effect of
benzothiazole starting material (benzothiazole-2-acetonitrile) on cell viability. Figure 21
shows the result obtained from the benzothiazole starting material. The LC50 value of the
starting material (0.2 mg/ml) is approximately two times higher than the LC50 value of the
tested compound with the highest LC50 value (PKP6).
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Cells/380 mm2

*

Figure 21 The effects of benzothiazole starting material on U-87MG glioblastoma
cells compared to untreated U-87MG cells. Red arrow indicates the LC50 value of
the starting material. Asterisk represents the lowest concentration with a
statistically significant difference from control, p ≤ 0.05. Error bars indicate
standard error, n=3 independent experiments in triplicate.

Confirmation of Lethal Concentration (LC50)
To ensure that the LC50 values obtained from the linear regression using data from
the cell viability assay were accurate, concentrations of each compound at the calculated
LC50 values were verified with nine replicates. Figure 22 shows that while most
compounds were within the 50% cell viability range, PKP2 was well below the range
(27.7%).
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Figure 22 Confirmation of LC50 values for eight novel hybrid benzothiazole
compounds. Cell viability was measured at the predicted LC50 for each of the
eight novel hybrid benzothiazoles. Each bar represents the mean and standard
error for nine independent replicates.

As seen in Figure 22, the cell viability of PKP2 was much lower when U-87MG
glioblastoma cells were treated nine times at the initial LC50 value. As a result, PKP2 was
tested again using the modified NIH cell viability assay to redefine its LC50 value. Figure

Cells/380 mm2

23 shows the new LC50 value (0.026561 mg/ml) obtained from linear regression.

Figure 23 Redefined LC50 of PKP2. U-87MG were treated with PKP2 following the
modified NIH cell viability assay. Red arrow indicates the LC50 value of the
compound. Error bars indicate standard error, n = 3 independent experiments in
triplicate
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Wound Healing Scratch Assay
Analysis of cell migration via wound healing scratch assay was used to quantify
the alterations in cell migratory capacity in response to treatment with novel hybrid
benzothiazoles. The results however showed not migration but rather the present or
absence of cells in the scratch. Figure 24 shows the results of untreated cells while Figure
25 shows a representative plate of treated cells. Treated plates filled in the scratch at the
same extent as the control plate.

850 µm
820 µm

B

B

A

Figure 24 Scratch Assay – Untreated.
A) Day one B) Day two

Figure 25 Scratch Assay - Treated (PKP3)
A) Day one B) Day two

Neurosphere Assay
To determine the effect of the tested compounds on the formation of
neurospheres, U-87MG cells were treated with the LC50 and LTC of each novel hybrid
benzothiazoles (Table 1). Table 5 shows the neurosphere formation at LTC. While no
significant difference between treated and untreated compounds seem to be present,
PKP4, PKP5, and PKP6 showed the delay in the formation of neurospheres.
Table 6 shows the neurosphere formation at the LC50. Neurospheres were absent
day 1 for all compounds while two small neurospheres were present in the control. There
were no neurospheres present at day 3 for all compounds with the exception of PKP4,
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PKP5, and PKP6 which had small neurospheres or the initial neurosphere formation
(where U-87MG cells are beginning to form a neurosphere can be observed), while two
medium neurospheres were present in the control. On day 6, PKP2, PKP5, and PKP7 had
neuropsheres that were beginning their formation, PKP3 and PKP6 lacked neurospheres,
and 4F-3BA, 3F-2BA and PKP4 had one small neurosphere. In contrast, the whole well
was covered with neurospheres in the control.

Table 5 Effect of Novel Hybrid Benzothiazoles on Formation of Neurosphere at Lowest
Tested Concentration
DAY 1

DAY 3

DAY 6

PKP2

+, starting

+, medium

+, large

PKP3

+, starting

+ +, small

+, large

PKP4

Absent

+, small

+, medium

PKP5

Absent

+, medium

+, large, +, small

PKP6

Absent

+, small-medium

+, medium, + +, small

PKP7

+, starting

+, small

+, large, +, small

4F-3BA

+, small

+, medium

Whole well covered

3F-2BA

+, small

+, medium

+, large

CONTROL

+, small

+, medium

Whole well covered
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Table 6 Effect of Novel Hybrid Benzothiazoles on Formation of Neurosphere at LC50
COMPOUND + LC50

DAY 1

DAY 3

DAY 6

PKP2 (0.02656 MG/ML)

Absent

Absent

+, starting

PKP3 (0.03215 MG/ML)

Absent

Absent

Absent

PKP4 (0.0625 MG/ML)

Absent

+, starting

+, small

PKP5 (0.0625 MG/ML)

Absent

+, small

+, starting

PKP6 (0.09375 MG/ML)

Absent

+, small

Absent

PKP7 (0.0875 MG/ML)

Absent

Absent

+, starting

4F-3BA (0.01171 MG/ML)

Absent

Absent

+, small

3F-2BA (0.05625 MG/ML)

Absent

Absent

+, small

+ +, small

+ +, medium

Whole well
covered

CONTROL

500 μm

Figure 26 Representation of the sizes and description of neurosphere formation.
Red line for scale.
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Invasion Assay
To determine the anti-invasive properties of the tested compounds, U-87MG cells
were treated with HCRC (Table 2). Figure 24 shows the effect of the tested compounds
on the cell’s invasive properties. PKP2 and PKP3 both possessing boronic acid
substituents at the para or meta positions and PKP5 which contain fluoro substituent at
ortho position display a statistically significant decrease in the percentage of invasive
cells. While PKP4, PKP6, and PKP7 display a decrease in the number of invasive cells,
the differences are not statistically significant.

*

*

*

Figure 27 Anti-invasive property of tested compounds. U-87MG cells were
treated with six compounds at their HCRC values. Statistically significant
difference (P ≤ 0.05 for one-way ANOVA) between untreated cells and tested
compounds are indicated by an asterisk. Error bars indicate standard error, n= 3
individual experiments done in duplicate wells for each experiment.
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CHAPTER 4

DISCUSSION

Predicted Bioavailability and Blood-brain barrier Permeability of Novel Hybrid
Benzothiazoles
Lipophilicity
As discussed, lipophilicity of a compound plays an important role in the
bioavailability and blood-brain barrier permeability. Higher lipophilicity has been shown
to allow higher permeability in the gastrointestinal tract and across the blood-brain barrier
(Winiwarter et al., 2007). However, if the lipophilicity is too high (LogP>5), this could
result in high metabolic turnover, low solubility, and poor oral absorption as well as
toxicity from inappropriate target interactions. Low lipophilicity, on the other hand, could
also affect negatively on potency and permeability of a compound which results in
reduced/poor bioavailability and efficacy. Compounds with LogP less than 4 and greater
than 1 has been shown to have optimal physicochemical properties for oral drugs (Gao et
al., 2016). As shown in Table 1, novel hybrid benzothiazoles are all highly lipophilic.
However, while most compounds fall within the range of LogP value with the optimal
physicochemical properties, PKP6 and PKP7 are slightly above the optimal range.
Therefore I believe all tested compounds, with the exception of PKP6 and PKP7, will
most likely have the optimal physicochemical properties for oral drugs.
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Oral Bioavailability
The number of hydrogen-bond donor (nOHNH) for all novel hybrid
benzothiazoles are well below 5 and are in accordance with Lipinski’s rule. All novel
hybrid benzothiazoles have molecular weight of less than 500 which would allow them to
be easily transported, diffused and absorbed as compared to those that are greater 500.
LogP, as mentioned previously, determines the lipophilicity of novel hybrid
benzothiazoles. All novel hybrid benzothiazoles have been shown to have LogP values
that are less than 5, in accordance with Lipinski’s rule. The number of hydrogen-bond
acceptors for all novel hybrid benzothiazoles is less than 10. None of the novel hybrid
benzothiazoles violated Lipinski’s rule.
Moreover, novel hybrid benzothiazoles meet the two additional extensions of
Lipinski’s rules. All three types have less than 10 rotatable bonds and their topological
polar surface area (TPSA) values range from 53-77 Å. TPSA has been correlated with
hydrogen bonding of the molecules and is a reliable indicator of the bioavailability,
gastrointestinal absorption, and blood-brain barrier penetration of a compound. Using the
TPSA I calculated the percent absorption using the equation provided by Zhao et al.
(2002). The calculated percent absorption for novel hybrid benzothiazoles ranged
between 82.38-96.34%, indicating good oral bioavailability.

Blood-brain Barrier Penetration
Blood-brain barrier penetration properties of a compound can be predicted using
the quantitative structure-activity relationship (QSAR). Hansch and Fujita (1964) have
shown that the critical components for the blood-brain barrier penetration include
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lipophilicity, hydrogen bonding, and molecular weight. Generally, compounds that are
moderately lipophilic can cross the blood-brain barrier through passive diffusion. As
mentioned above, lipophilicity of a compound can be determined by LogP. Pike (2009)
has shown that the blood-brain barrier penetration is optimal when the LogP values are
within the threshold of 2-3.5.
Molecular weight is another critical component for blood-brain barrier (BBB)
penetration. Compounds with a molecular weight less than 450 is needed to facilitate
BBB penetration and lower for better oral absorption (Atkinson et al., 2002). Hydrogen
bonding properties of a compound can also play a significant role in the CNS uptake
profile. Polar molecules are often poor CNS agents, unless they are transported across the
CNS by active transport (Pajouhesh and Lenz, 2005). Polar surface area (PSA) has also
been used to predict BBB penetration. Generally, compounds with lower PSA have been
shown to be more effective at penetration of the BBB. The optimal PSA for BBB
penetration has been estimated at 60-70 Å through 90 Å (Mouritsen and Jorgensen,
1998).
Based on the LogP values, all novel hybrid benzothiazoles, except for those with
just fluoro substituents (PKP5-7) fall within the optimal blood-brain barrier penetration
threshold. According to the previous studies, the BBB penetration is optimal within the
LogP value range of 2-3.5. The LogP values of novel hybrid benzothiazoles ranges
between 2.77-4.11. PSA values of all tested novel hybrid benzothiazoles, except for those
with only fluoro substituent (PKP5-7), fall within the estimated optimal PSA range. In
terms of molecular weight, all of novel hybrid benzothiazoles meet the condition to
facilitate the BBB penetration; they are all less than 450.
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Chemistry
Benzothiazole α-cyanostilbenes synthesis was achieved via base-catalyzed
Knoevenagel condensation reaction. Knoevenagel condensation reaction is a nucleophilic
addition of an active hydrogen atom to a carbonyl group, aldehyde in this specific
reaction, with a base catalyst (Jones, 2011). This addition is then followed by elimination
of a water molecule through the dehydration reaction (Fig 27).

Figure 27 Mechanism of Knoevenagel Condensation reaction which occurs in the
synthesis of hybrid benzothiazole a-cynanostilbene. Boronic acid substituent is used as
an example.

The design and synthesis of benzothiazole α-cyanostilbenes were focused on
covalently linking benzothiazole-2-acetonitrile and an aromatic aldehyde with or without
boronic acid substituents to produce novel hybrid molecules. Various functional groups
such as boronic acid, fluoro, chloro at ortho, meta, or para positions were synthesized for
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comparison. Such comparisons are noted between PKP2, PKP3, PKP4, PKP5, PKP6,
PKP7, 4F-3BA, and 3F-2BA. All of these compounds had a merged benzothiazolestilbene scaffold. However, PKP2, PKP3, and PKP4 have boronic acid substituent,
whereas PKP5, PKP6, and PKP7 have fluoro substituent. 4F-3BA and 3F-2BA contain
both boronic acid and fluoro substituents. Boronic acid was chosen as a substituent
because of their success as FDA approved anti-cancer drugs (i.e. Ixazomib and
Bortezomib). Fluoro substituents were chosen because of their ability to enhance a
number of pharmacokinetic and physiochemical properties including enhanced
membrane permeation and improved metabolic stability (Shah and Westwell, 2007).
Catalyst and solvent used in the process of Knoevenagel condensation reaction
plays an important role in the percentage yield of the products. Evidences of the
importance of the base catalyst can be seen in multiple studies with modified
Knoevenagel reaction. For example, Rao and Venkataratnam (1991), utilized zinc
chloride as a catalyst for their modified Knoevenagel condensation reaction and obtained
products of good purity and high in yield. Schenider et al. (2015) reported the use of
copper metal surfaces as their catalyst in their modified Knoevenagel reactions. Their
study tested pure copper metal powder and compared it against carbon coated-copper
nanoparticles (C/Cu) which has been shown to produce the highest activity in the
Knoevenagel reaction (Koehler et al., 2009). Reactions catalyzed by pure metal powder
showed higher yield and time efficiency. Panja et al. (2015) compared several different
solvents for their Knoevenagel reactions such as the use of water, acetonitrile,
dichloromethane, ethanol and solvent-free conditions. Their report indicated that the
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solvent which optimized the reaction best was ethanol with the reaction time of 3 mins at
room temperature and 98% yield.
In this project, calcium oxide was used as the base catalyst and ethanol and water
were used as the solvents. The percentage yields obtained from the synthesis of the
benzothiazole α-cyanostilbenes ranged from 49.78% to 116.60%. All benzothiazole αcyanostilbenes were synthesized under the same conditions (catalyst, solvent, and time).
Based on the literature for optimizing percentage yields, it is possible to increase the
compound with 49% yield. Varying reaction conditions such as reaction time, catalyst,
and/or solvent could have resulted in increased percent yield of the product.
4F-3BA, with the highest percent yield of 116.60% and other compounds with
percent yield over 100% could have produced higher yields due to the presence of
impurities. The impurities in the product could have been the calcium oxide catalyst.
These compounds were further purified by utilizing separation techniques and washing
techniques in ethyl acetate as a solvent. All compounds that were purified had a decrease
in percent yield by half of the initial percent yield. This may be the result of product loss
during the purification process. Purification techniques which optimize product retention
should be explored in future studies. Furthermore, changing the catalyst to calcium
hydride or calcium hydroxide can decrease the presence of the catalyst in the product.
Styrylbenzothiazole were synthesized using the aldol-type condensation reaction.
Aldol-type condensation is the reaction of a stabilized carbanion ion and a carbonyl
group which forms a β-hydroxyl (ketone/aldehyde) and water (Jones and Fleming, 2010).
Figure 28 shows the general mechanism of Aldol-type condensation reaction which
occurs in the synthesis of hybrid styrylbenzothiazoles.
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Figure 28 Mechanism of Aldol-type condensation reaction which occurs in the
synthesis of hybrid styrylbenzothiazole. Boronic acid substituent is used as an
example.

In the synthesis of styrylbenzothiazoles, no catalyst was used, and the reaction
occurred at room temperature in four hours. While I was able to obtain products for
chloro, fluoro, and trifluoromethyl substituents, I was unable to successfully produce
products containing boronic acid substituents. In the initial experiment in the synthesis of
styrylbenzothiazoles, I used dimethylformamide (DMF) as the solvent and potassium tbutoxide (KTB) and lithium hydride (LiH) to deprotonate and to produce enolate ions.
However, I obtained low percent yield for all the products and they were sticky in
texture. To optimize the percent yield and to solve the texture problem, I opted for using
just LiH without KTB. This produced better results. The percent yield obtained from the
modified method ranged from 72% to 97%. However, I was not able to successfully
synthesize styrylbenzothiazole containing boronic acid substituent. When analyzed under
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NMR and IR, the absence of boronic acid was noted. The cause of deboronation is still
unknown and needs further exploration.

Biological Evaluation
In recent years, benzothiazole derivatives have been explored as potential new
therapies with various biological activities against infection, osteoarthritis, and cancer
(Bondock et al., 2010; Brantley et al., 2006; Vicini et al., 2011). Benzothiazole
analogues, such as tetrahydrobenzothiazoles have been tested as potential anti-tumor
drugs via inhibition of mutated p53 activity to enhance paclitaxel-induced apoptosis
(Christodoulou et al., 2011). In addition, benzothiazole derivatives have been shown to
produce cytotoxicity in human cancer cell lines in vitro (Kok et al., 2008) and act as
potent growth inhibitors in a number of human-derived cancer cell lines (Hu et al., 2010;
Tzanopoulou et al., 2010).
The results from this study confirm the biological activity of the novel hybrid
benzothiazole structure. I have shown the potential anti-cancer effect of a new series of
hybrid benzothiazoles in U-87MG glioblastoma cells. All tested compounds showed a
decrease in cell viability. Based on the modified NIH cell viability assay, 4F-3BA,
benzothiazole α-cyanostilbenes, containing both fluoro and boronic acid substituent on
the aromatic ring, was the most effective compound tested (LC50: 36.25 μM),
immediately followed by PKP2 which contains boronic acid substituent at para position
(LC50:86.76 μM). This outcome could imply that fluoro-containing compounds had
enhanced pharmacokinetic and physiochemical properties. Fluorines have been shown to
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influence permeability and potency of compounds due to its high electronegativity and
high lipophilicity (Gillis et al., 2015).
Overall, there was no clear correlation between the potency of the compound and
the substituent’s position on the aromatic ring. However, in compounds with boronic acid
substituent, para position has the highest potency (LC50:86.76 μM) while ortho position
had the lowest potency (LC50: 280.33 μM). In compounds with fluoro substituent, ortho
position had the highest potency (LC50: 280.33 μM) and para position has the lowest
potency (LC50: 334.42 μM). In general, compounds containing boronic acid substituents
seem to favor the cytotoxic activity more than compounds containing fluoro substituents,
since PKP2, PKp3, and PKP4 were more active than PKP5, PKP6, and PKP7.
Neurospheres play an important role in multilineage differentiation in neural cells
(Ishiguro et al., 2017). They are highly heterogeneous entities which produce the same
cellular components of neural stem cells. Due to their abilities that mimic that of neural
stem cells, they have been highly exploited in drug screening (Galli, 2013).
In this project, U-87MG glioblastoma cells were treated with LC50 and LTC of the
tested compounds to determine their effects on the formation of neurospheres. At the
LTC, there appears to be no significant difference between treated and untreated
compounds. However, PKP4, PKP5, and PKP6 seems to slightly decrease the formation
of neurospheres compared to the other three tested compounds. Regardless, it does not
take away from the fact that none of the compounds were able to significantly reduce
neurosphere formation. At the LC50, there is a significant reduction of neutrosphere
formation in treated compounds. All tested compounds appear to inhibit the formation of
neurospheres at the same rate. This may be the result of 50% cell viability which prevents
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the formation of neurospheres or the reduced number of neurospheres could be the cause
of the reduced cell numbers and should be investigated further.
As discussed in Chapter 1, one of the hallmarks of cancer is invasion and
metastasis. Invasion and metastasis, in the context of GBM, plays a vital role in cancer
progression and recurrence. None of novel hybrid benzothiazoles seems to inhibit or
prevent cell migration as seen in the wound healing scratch assay. However, it is possible
that the assay was not measuring the motility of the cells but instead their proliferation.
Further modification of the assay is needed to be explored to accurately measure the
migration of the cells. One area of modification could be the media used. By using serum
free medium instead of serum containing fetal bovine serum, the assay could be made to
measure only the migration of the cell.
Three of the novel hybrid benzothiazoles (PKP2, PKP3, and PKP5) seem to
decrease the number of invasive cells, as shown in the invasion assay. These three
promising compounds warrant further detailed analyses to elucidate the underlying
molecular mechanism of action. Moreover, due to the literature reports of benzothiazoles
analogs with the abilities to induce apoptosis, novel hybrid benzothiazoles should be
tested for the underlaying mechanism of the cause of cell death.
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CHAPTER 5

CONCLUSION
As disclosed in Chapter 1, glioblastoma multiforme is highly lethal due to its
aggressive and invasive proliferation. A major factor shaping the high mortality lies in
cancer cells’ ability to migrate and to proliferate. Therefore, development of cancer
therapies targeting invasion and induction of apoptosis is necessary.
In this study, 19 novel hybrid benzothiazole α-cyanostilbenes with or without
boronic acid substituents and 7 novel hybrid styrylbenzothiazoles without boronic acid
substituents were synthesized and described. Out of the total synthesized compounds, 8
novel hybrid benzothiazole α-cyanostilbenes were screened for their anti-cancer
activities. The result of the project demonstrated the anti-cancer activity of novel hybrid
benzothiazole derivatives, particularly compound 4F-3BA, which had the highest potency
in vitro.
Based on the neurosphere assay, at LTC (0.00195 mg/ml) PKP4 (boronic acid at
meta position), PKP5 (fluoro at ortho position), and PKP6 (fluro at para position) were
the most successful compounds in delaying the formation of the neurospheres. At LC50
all tested compounds were effective at preventing the formation of the neurospheres, with
PKP4 (boronic acid at meta position) and PKP5 (fluoro at ortho position) being the least
effective compounds.
The result of the invasion assay showed that three compounds, PKP2 (boronic
acid at para position), PKP3 (boronic acid at ortho position) and PKP5 ( display some
anti-invasive properties. The anti-invasive properties of these three compounds should be
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further evaluated by a more reliable invasion assay which utilizes Calcein fluorescence to
quantify the number of invasive cells. All 8 tested compounds should be further tested to
determine their effect on caspases to explore their potential as apoptotic inducing agents.
In addition, all novel hybrid benzothiazoles should be further studied for their anti-cancer
properties and verify the underlying mechanism of action.
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Multiple Comparisons (PKP2)
Dependent Variable: Cells
Dunnett t (2-sided)a

Mean

95% Confidence Interval

(I)

(J)

Concentration

Concentration

2 mg/ml

Control

-176.00000* 15.18273

.000

-221.0579

-130.9421

1 mg/ml

Control

-176.00000* 15.18273

.000

-221.0579

-130.9421

Control

-176.00000*

15.18273

.000

-221.0579

-130.9421

0.25

Control

-100.00000*

15.18273

.000

-145.0579

-54.9421

0.125 mg/ml

Control

-97.89000* 15.18273

.000

-142.9479

-52.8321

0.0625

Control

-73.00000* 15.18273

.001

-118.0579

-27.9421

0.03125

Control

-19.89000

15.18273

.765

-64.9479

25.1679

0.01562

Control

-13.00000

15.18273

.972

-58.0579

32.0579

0.00781

Control

-35.66667

15.18273

.174

-80.7246

9.3912

0.003906

Control

-26.11000

15.18273

.483

-71.1679

18.9479

0.00195

Control

-3.44333

15.18273

1.000

-48.5012

41.6146

0.5 mg/ml

Difference (IJ)

Std. Error

Sig.

Lower Bound Upper Bound

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
Multiple Comparisons (PKP3)
Dependent Variable: Cells
Dunnett t (2-sided)a
Mean

95% Confidence Interval

(I)

(J)

Difference (I-

Concentration

Concentration

2 mg/ml

Control

-83.66767

38.93939

.249

-199.2284

31.8930

1 mg/ml

Control

-133.77667*

38.93939

.018

-249.3374

-18.2160

0.5 mg/ml

Control

-145.77667*

38.93939

.008

-261.3374

-30.2160

0.25

Control

-156.77767*

38.93939

.004

-272.3384

-41.2170

0.125 mg/ml

Control

-121.33333*

38.93939

.036

-236.8940

-5.7726

0.0625

Control

-71.89000

38.93939

.404

-187.4507

43.6707

0.03125

Control

-66.44333

38.93939

.492

-182.0040

49.1174

0.01562

Control

-34.89000

38.93939

.963

-150.4507

80.6707

0.00781

Control

-42.78000

38.93939

.888

-158.3407

72.7807

J)

Std. Error
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Sig.

Lower Bound Upper Bound

0.003906

Control

-42.44333

38.93939

.893

-158.0040

73.1174

0.00195

Control

-39.11333

38.93939

.929

-154.6740

76.4474

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
Multiple Comparisons (PKP4)
Dependent Variable: Cells
Dunnett t (2-sided)a
Mean
(I)

(J)

Concentration

Concentration

95% Confidence Interval

Difference (IJ)

Std. Error

Sig.

Lower Bound Upper Bound

2 mg/ml

Control

-157.55333*

1 mg/ml

Control

-154.11000*

41.65868

.009

-277.7407

-30.4793

0.5 mg/ml

Control

-181.33333*

41.65868

.002

-304.9641

-57.7026

Control

-207.11000*

41.65868

.000

-330.7407

-83.4793

0.125 mg/ml

Control

-182.77667*

41.65868

.002

-306.4074

-59.1459

0.0625

Control

-105.00000

41.65868

.126

-228.6307

18.6307

0.03125

Control

-102.11333

41.65868

.144

-225.7441

21.5174

0.01562

Control

-88.66667

41.65868

.257

-212.2974

34.9641

0.00781

Control

-79.11333

41.65868

.373

-202.7441

44.5174

0.003906

Control

-76.22000

41.65868

.413

-199.8507

47.4107

0.00195

Control

-33.77667

41.65868

.980

-157.4074

89.8541

0.25

41.65868

.008

-281.1841

-33.9226

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.

Multiple Comparisons (PKP5)
Dependent Variable: Cells
Dunnett t (2-sided)a
Mean
(I)

(J)

Concentration

Concentration

95% Confidence Interval

Difference (IJ)

Std. Error

Sig.

Lower Bound Upper Bound

2 mg/ml

Control

-187.66667*

1 mg/ml

Control

-187.66667*

34.29165

.000

-289.4342

-85.8991

0.5 mg/ml

Control

-166.77778*

34.29165

.001

-268.5453

-65.0102

Control

-160.33333*

34.29165

.001

-262.1009

-58.5658

0.125 mg/ml

Control

-136.88889*

34.29165

.005

-238.6564

-35.1213

0.0625

Control

-95.77778

34.29165

.072

-197.5453

5.9898

0.03125

Control

-69.88890

34.29165

.299

-171.6565

31.8787

0.25

34.29165

.000

-289.4342

-85.8991
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0.01562

Control

-35.77777

34.29165

.914

-137.5453

65.9898

0.00781

Control

14.55557

34.29165

1.000

-87.2120

116.3231

0.003906

Control

.88890

34.29165

1.000

-100.8787

102.6565

0.00195

Control

-9.22223

34.29165

1.000

-110.9898

92.5453

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
Multiple Comparisons (PKP6)
Dependent Variable: Cells
Dunnett t (2-sided)a
Mean

95% Confidence Interval

(I)

(J)

Concentration

Concentration

2 mg/ml

Control

-236.11000* 37.02171

.000

-345.9796

-126.2404

Control

-235.00000*

37.02171

.000

-344.8696

-125.1304

0.5 mg/ml

Control

-219.00000*

37.02171

.000

-328.8696

-109.1304

0.25

Control

-150.22333* 37.02171

.004

-260.0929

-40.3538

0.125 mg/ml

Control

-124.22000* 37.02171

.021

-234.0896

-14.3504

0.0625

Control

-105.44667

37.02171

.065

-215.3162

4.4229

0.03125

Control

-44.11000

37.02171

.839

-153.9796

65.7596

0.01562

Control

-52.44333

37.02171

.693

-162.3129

57.4262

0.00781

Control

-11.44333

37.02171

1.000

-121.3129

98.4262

0.003906

Control

28.55333

37.02171

.986

-81.3162

138.4229

0.00195

Control

24.33333

37.02171

.996

-85.5362

134.2029

1 mg/ml

Difference (IJ)

Std. Error

Sig.

Lower Bound Upper Bound

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
Multiple Comparisons (PKP7)
Dependent Variable: Cells
Dunnett t (2-sided)a
Mean
(I)

(J)

Concentration

Concentration

95% Confidence Interval

Difference (IJ)

Std. Error

Sig.

Lower Bound Upper Bound

2 mg/ml

Control

-193.66667*

54.44449

.013

-355.2419

-32.0914

1 mg/ml

Control

-192.89000* 54.44449

.014

-354.4653

-31.3147

0.5 mg/ml

Control

-180.33333* 54.44449

.023

-341.9086

-18.7581

0.25

Control

-149.78000

54.44449

.079

-311.3553

11.7953

0.125 mg/ml

Control

-109.88667

54.44449

.309

-271.4619

51.6886

112

0.0625

Control

-58.44333

54.44449

.900

-220.0186

103.1319

0.03125

Control

-53.99667

54.44449

.934

-215.5719

107.5786

0.01562

Control

-32.33333

54.44449

.998

-193.9086

129.2419

0.00781

Control

-2.55433

54.44449

1.000

-164.1296

159.0209

0.003906

Control

2.55667

54.44449

1.000

-159.0186

164.1319

0.00195

Control

-66.44333

54.44449

.822

-228.0186

95.1319

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
Multiple Comparisons (4F-3BA)
Dependent Variable: Cells
Dunnett t (2-sided)a
Mean
(I)

(J)

Concentration

Concentration

95% Confidence Interval

Difference (IJ)

Std. Error

Sig.

Lower Bound Upper Bound

2 mg/ml

Control

-117.77778*

17.11267

.000

-168.5632

-66.9924

1 mg/ml

Control

-125.44445* 17.11267

.000

-176.2298

-74.6591

0.5 mg/ml

Control

-127.44444* 17.11267

.000

-178.2298

-76.6591

Control

-129.11111*

17.11267

.000

-179.8965

-78.3257

0.125 mg/ml

Control

-116.11111*

17.11267

.000

-166.8965

-65.3257

0.0625

Control

-80.44444* 17.11267

.001

-131.2298

-29.6591

0.03125

Control

-71.44444* 17.11267

.003

-122.2298

-20.6591

Control

-80.33333*

17.11267

.001

-131.1187

-29.5479

0.00781

Control

-56.33334*

17.11267

.024

-107.1187

-5.5480

0.003906

Control

-41.66667

17.11267

.148

-92.4521

9.1187

0.00195

Control

-43.11110

17.11267

.126

-93.8965

7.6743

0.25

0.01562

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
Multiple Comparisons (3F-2BA)
Dependent Variable: Cells
Dunnett t (2-sided)a
Mean

95% Confidence Interval

(I)

(J)

Concentration

Concentration

2 mg/ml

Control

-151.55556*

25.28414

.000

-226.5915

-76.5196

Control

-150.66667*

25.28414

.000

-225.7026

-75.6308

Control

-147.66667*

25.28414

.000

-222.7026

-72.6308

1 mg/ml
0.5 mg/ml

Difference (IJ)

Std. Error
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Sig.

Lower Bound Upper Bound

0.25

Control

-112.44444*

25.28414

.002

-187.4804

-37.4085

0.125 mg/ml

Control

-83.55556*

25.28414

.024

-158.5915

-8.5196

0.0625

Control

-77.88889*

25.28414

.039

-152.9248

-2.8530

0.03125

Control

-60.44445

25.28414

.161

-135.4804

14.5915

0.01562

Control

-61.88890

25.28414

.145

-136.9248

13.1470

0.00781

Control

-48.44446

25.28414

.363

-123.4804

26.5915

0.003906

Control

-28.33334

25.28414

.878

-103.3693

46.7026

0.00195

Control

-40.11111

25.28414

.573

-115.1470

34.9248

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
Multiple Comparisons (PKP2 revised)
Dependent Variable: Cells
Dunnett t (2-sided)a
Mean

95% Confidence Interval

(I)

(J)

Concentration

Concentration

2 mg/ml

Control

-141.50000*

5.76749

.000

-160.0670

-122.9330

Control

-141.33333*

5.76749

.000

-159.9003

-122.7664

0.5 mg/ml

Control

-141.16667*

5.76749

.000

-159.7336

-122.5997

0.25

Control

-140.66667*

5.76749

.000

-159.2336

-122.0997

0.125 mg/ml

Control

-141.00000*

5.76749

.000

-159.5670

-122.4330

Control

-126.50000*

5.76749

.000

-145.0670

-107.9330

0.03125

Control

-53.50000*

5.76749

.000

-72.0670

-34.9330

0.01562

Control

-45.50002*

5.76749

.000

-64.0670

-26.9331

0.00781

Control

-43.49998*

5.76749

.000

-62.0669

-24.9330

Control

-38.00000*

5.76749

.000

-56.5670

-19.4330

Control

-39.16665*

5.76749

.000

-57.7336

-20.5997

1 mg/ml

0.0625

0.003906
0.00195

Difference (IJ)

Std. Error

Sig.

Lower Bound Upper Bound

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
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